Patents by Inventor Nicholas J. Lawrence

Nicholas J. Lawrence has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dimeric immuno-modulatory compounds against cereblon-based mechanisms
    Patent number: 12233054
    Abstract: Disclosed are small molecules against cereblon to enhance effector T cell function. Methods of making these molecules and methods of using them to treat various disease states are also disclosed.
    Type: Grant
    Filed: August 21, 2023
    Date of Patent: February 25, 2025
    Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
    Inventors: Pearlie Burnette, Nicholas J. Lawrence, Harshani Lawrence
  • BRD4-JAK2 inhibitors
    Patent number: 12187686
    Abstract: Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I, II, and II.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: January 7, 2025
    Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
    Inventors: Ernst Schönbrunn, Nicholas J. Lawrence, Harshani R. Lawrence, Gary Reuther
  • YAP1 inhibitors that target the interaction of YAP1 with OCT4
    Patent number: 11999695
    Abstract: Binding of the transcriptional co-activator, YAP1, to the transcription factor Oct4, induces Sox2, which is a transcription actor necessary for the self-renewal of stem-like cells from non-small cell lung cancer. The WW domain of YAP1 binds to the PPxY motif of Oct4 to induce Sox2. Delivering a peptide corresponding to the WW domain could prevent the induction of Sox2 and sternness. Similarly, peptides and mimetics of the PPxY motif would be able to inhibit sternness. Disclosed are compounds that affect the Yap1:Oct4 interaction.
    Type: Grant
    Filed: December 19, 2022
    Date of Patent: June 4, 2024
    Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
    Inventors: Srikumar Chellappan, Nicholas J. Lawrence, Sujeewa Ranatunga Mahanthe Mudiyanselage
  • Dimeric immuno-modulatory compounds against cereblon-based mechanisms
    Patent number: 11730726
    Abstract: Disclosed are small molecules against cereblon to enhance effector T cell function. Methods of making these molecules and methods of using them to treat various disease states are also disclosed.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: August 22, 2023
    Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
    Inventors: Pearlie Burnette, Nicholas J. Lawrence, Harshani Lawrence
  • SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION
    Publication number: 20230226035
    Abstract: Disclosed are small molecules against cereblon to enhance effector T cell function. Methodos of making thes molecules and methods of using them to treat various disease states are also disclosed.
    Type: Application
    Filed: June 7, 2022
    Publication date: July 20, 2023
    Inventors: Pearlie Burnette, Harshani Lawrence, Nicholas J. Lawrence
  • YAP1 inhibitors that target the interaction of YAP1 with OCT4
    Patent number: 11685725
    Abstract: Binding of the transcriptional co-activator, YAP1, to the transcription factor Oct4, induces Sox2, which is a transcription actor necessary for the self-renewal of stem-like cells from non-small cell lung cancer. The WW domain of YAP1 binds to the PPxY motif of Oct4 to induce Sox2. Delivering a peptide corresponding to the WW domain could prevent the induction of Sox2 and sternness. Similarly, peptides and mimetics of the PPxY motif would be able to inhibit sternness. Disclosed are compounds that affect the Yap1:Oct4 interaction.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: June 27, 2023
    Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
    Inventors: Srikumar Chellappan, Nicholas J. Lawrence, Sujeewa Ranatunga Mahanthe Mudiyanselage
  • BRD4-kinase inhibitors as cancer therapeutics
    Patent number: 11643396
    Abstract: Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: May 9, 2023
    Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
    Inventors: Ernst Schönbrunn, Nicholas J. Lawrence, Harshani R. Lawrence
  • Platinum compounds that inhibit constitutive STAT3 signaling and induce cell cycle arrest and apoptosis of malignant cells
    Patent number: 11571418
    Abstract: The subject invention concerns a compound and compositions having activity as an inhibitor of Stat3 protein and methods of using the compound and compositions. In one embodiment, a compound of the invention has the structure shown in formula I, formula II, or formula III. The subject invention also concerns methods of using the compounds and compositions of the invention.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: February 7, 2023
    Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Said M. Sebti, Nicholas J. Lawrence, James Turkson
  • YAP1 inhibitors that target the interaction of YAP1 with Oct4
    Patent number: 11530182
    Abstract: Binding of the transcriptional co-activator, YAP1, to the transcription factor Oct4, induces Sox2, which is a transcription actor necessary for the self-renewal of stem-like cells from non-small cell lung cancer. The WW domain of YAP1 binds to the PPxY motif of Oct4 to induce Sox2. Delivering a peptide corresponding to the WW domain could prevent the induction of Sox2 and stemness. Similarly, peptides and mimetics of the PPxY motif would be able to inhibit sternness. Disclosed are compounds that affect the Yap1:Oct4 interaction.
    Type: Grant
    Filed: December 30, 2020
    Date of Patent: December 20, 2022
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Srikumar Chellappan, Nicholas J. Lawrence, Sujeewa Ranatunga Mahanthe Mudiyanselage
  • Small molecules against cereblon to enhance effector t cell function
    Patent number: 11395820
    Abstract: Disclosed are small molecules against cereblon to enhance effector T cell function. Methods of making these molecules and methods of using them to treat various disease states are also disclosed.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: July 26, 2022
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Pearlie Burnette, Harshani Lawrence, Nicholas J. Lawrence
  • SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION
    Publication number: 20210177825
    Abstract: Disclosed are small molecules against cereblon to enhance effector T cell function. Methods of making these molecules and methods of using them to treat various disease states are also disclosed.
    Type: Application
    Filed: March 16, 2017
    Publication date: June 17, 2021
    Inventors: Pearlie Burnette, Harshani Lawrence, Nicholas J. Lawrence
  • YAP1 inhibitors that target the interaction of YAP1 with OCT4
    Patent number: 10906874
    Abstract: Binding of the transcriptional co-activator, YAP1, to the transcription factor Oct4, induces Sox2, which is a transcription actor necessary for the self-renewal of stem-like cells from non-small cell lung cancer. The WW domain of YAP1 binds to the PPxY motif of Oct4 to induce Sox2. Delivering a peptide corresponding to the WAV domain could prevent the induction of Sox2 and stemness. Similarly, peptides and mimetics of the PPxY motif would be able to inhibit stemness. Disclosed are compounds that affect the Yap1:Oct4 interaction.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: February 2, 2021
    Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
    Inventors: Srikumar Chellappan, Nicholas J. Lawrence, Sujeewa Ranatunga Mahanthe Mudiyanselage
  • BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS
    Publication number: 20200407328
    Abstract: Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.
    Type: Application
    Filed: June 5, 2020
    Publication date: December 31, 2020
    Inventors: Ernst Schönbrunn, Nicholas J. Lawrence, Harshani R. Lawrence
  • Platinum compounds that inhibit constitutive STAT3 signaling and induce cell cycle arrest and apoptosis of malignant cells
    Patent number: 10813927
    Abstract: The subject invention concerns a compound and compositions having activity as an inhibitor of Stat3 protein and methods of using the compound and compositions. In one embodiment, a compound of the invention has the structure shown in formula I, formula II, or formula III. The subject invention also concerns methods of using the compounds and compositions of the invention.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: October 27, 2020
    Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Said M. Sebti, Nicholas J. Lawrence, James Turkson
  • BRD4-kinase inhibitors as cancer therapeutics
    Patent number: 10738016
    Abstract: Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: August 11, 2020
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Ernst Schönbrunn, Nicholas J. Lawrence, Harshani R. Lawrence
  • Potent dual BRD4-kinase inhibitors as cancer therapeutics
    Patent number: 10526291
    Abstract: Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: January 7, 2020
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Ernst Schönbrunn, Nicholas J. Lawrence, Harshani R. Lawrence, Gary W. Reuther
  • Inhibitors of ACK1/TNK2 tyrosine kinase
    Patent number: 10336734
    Abstract: Described are cancer therapies and anti-cancer compounds. In particular, disclosed are inhibitors of ACK1 tyrosine kinase and their use in the treatment of cancer. Methods of screening for new ACK1 tyrosine kinase inhibitors are also disclosed. In specific example, compound having Formula I are disclosed.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: July 2, 2019
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Nupam P. Mahajan, Kiran N. Mahajan, Nicholas J. Lawrence, Harshani R. Lawrence
  • POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS
    Publication number: 20190055203
    Abstract: Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.
    Type: Application
    Filed: October 22, 2018
    Publication date: February 21, 2019
    Inventors: Ernst Schönbrunn, Nicholas J. Lawrence, Harshani R. Lawrence
  • Potent dual BRD4-kinase inhibitors as cancer therapeutics
    Patent number: 10106507
    Abstract: Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: October 23, 2018
    Assignee: H. Lee Moffitt Cancer Center and Research Insitute, Inc.
    Inventors: Ernst Shönbrunn, Nicholas J. Lawrence, Harshani R. Lawrence
  • BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS
    Publication number: 20180290984
    Abstract: Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.
    Type: Application
    Filed: October 13, 2016
    Publication date: October 11, 2018
    Inventors: Ernst Schönbrunn, Nicholas J. Lawrence, Harshani R. Lawrence